VivoSeq
Other

Azoospermia

9

Pipeline Programs↗

3

Active Trials↗

8

Companies Involved↗

Azoospermia is an early-stage landscape with 9 programs across 8 companies. The most active players are Amgen, Kang Stem Biotech Co., Ltd., Ferring. 3 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

75/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 2K

Kang Stem Biotech Co., Ltd.

1 program

Phase 2Ferring logo

Ferring

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3V

Viatris Specialty LLC

1 program

ApprovedL

Leadiant Biosciences, Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

82%

Small molecule

9 of 11 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody19%Cell therapy19%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.

Analysis

Trial Status

10

clinical trials

Completed3 · 30%
Unknown status3 · 30%
Not yet recruiting1 · 10%
Withdrawn1 · 10%
Active, not recruiting1 · 10%
Recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Intra-Testicular Transplantation of Purified Autologous None Marrow-Derived, Highly Specialized Cellular Populations, and Mesenchymal Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility. Patients Diagnosed With Any of the Following Might Benefit: Sertoli Cell Only Syndrome (SCOS), Maturation Arrest, Post- Chemotherapy, Small Testes, Cystic Fibrosis Obstructive Azoospermia, Post-hormonal Therapy,
Recruiting·—·Preclinical·NCT02641769·600 enrolled
NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia
Active, not recruiting·—·Phase 1/2·NCT06706414·16 enrolled
Interest of Clomiphene Citrate in Patients With Non-obstructive Azoospermia on the Quantity of Sperm Cells
Not yet recruiting·HHospices Civils de Lyon·Phase 3·NCT03615547·128 enrolled
The Effects of Intratesticular PRP Injection in Men With Azoospermia or Cryptozoospermia
Completed·—·N/A·NCT04237779·200 enrolled
Effect of Letrozole on Seminal Parameters in Men With Non Obstructive Azoospermia and Severe Oligozoospermia.
Completed·KKK Women's and Children's Hospital·Phase 3·NCT02900105·28 enrolled
RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia
Completed·UUniversity of Washington·Phase 2·NCT03323801·10 enrolled
Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism
Withdrawn·UUniversity of Illinois at Chicago·N/A·NCT02137265
Clinical Research on Effectiveness and Safety of Treatment of Severe Oligospermia or Azoospermia With uFSH
Unknown status·LLivzon Pharmaceutical Group Inc.·Phase 4·NCT02307994·180 enrolled
GnRHa Combined With hCG and hMG for Treatment of Patients With Non-obstructive Azoospermia
Unknown status·JJinling Hospital, China·Phase 2·NCT02544191·30 enrolled
Testicular Injection of Autologous Stem Cells for Treatment of Patients With Azoospermia
Unknown status·—·Phase 1/2·NCT02041910·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)